Faron Pharmaceuticals Oy
FARN.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | – | – | – | – |
| R&D Expenses | £0 | £20 | £21 | £17 |
| G&A Expenses | £7 | £9 | £7 | £10 |
| SG&A Expenses | £7 | £9 | £7 | £10 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£7 | -£0 | -£1 | -£6 |
| Operating Expenses | £0 | £29 | £27 | £21 |
| Operating Income | -£0 | -£29 | -£27 | -£21 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -£0 | -£2 | -£1 | -£0 |
| Pre-Tax Income | -£0 | -£31 | -£29 | -£21 |
| Tax Expense | £0 | £0 | £1 | £0 |
| Net Income | -£0 | -£31 | -£29 | -£21 |
| % Margin | – | – | – | – |
| EPS | -0 | -0.34 | -0.38 | -0.29 |
| % Growth | 99.9% | 10.5% | -31% | – |
| EPS Diluted | -0 | -0.34 | -0.38 | -0.29 |
| Weighted Avg Shares Out | 89 | 79 | 67 | 61 |
| Weighted Avg Shares Out Dil | 89 | 79 | 67 | 61 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £1 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£28 | -£27 | -£21 |
| % Margin | – | – | – | – |